PT3508196T - Composições de pró-fármaco de aripiprazol - Google Patents

Composições de pró-fármaco de aripiprazol

Info

Publication number
PT3508196T
PT3508196T PT191540137T PT19154013T PT3508196T PT 3508196 T PT3508196 T PT 3508196T PT 191540137 T PT191540137 T PT 191540137T PT 19154013 T PT19154013 T PT 19154013T PT 3508196 T PT3508196 T PT 3508196T
Authority
PT
Portugal
Prior art keywords
aripiprazole
pro
drug compositions
drug
compositions
Prior art date
Application number
PT191540137T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51352472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3508196(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of PT3508196T publication Critical patent/PT3508196T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT191540137T 2014-08-18 2015-08-17 Composições de pró-fármaco de aripiprazol PT3508196T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14181328 2014-08-18

Publications (1)

Publication Number Publication Date
PT3508196T true PT3508196T (pt) 2021-08-25

Family

ID=51352472

Family Applications (1)

Application Number Title Priority Date Filing Date
PT191540137T PT3508196T (pt) 2014-08-18 2015-08-17 Composições de pró-fármaco de aripiprazol

Country Status (20)

Country Link
US (1) US12642798B2 (cg-RX-API-DMAC10.html)
EP (2) EP3508196B1 (cg-RX-API-DMAC10.html)
JP (1) JP6571166B2 (cg-RX-API-DMAC10.html)
CN (3) CN112494492B (cg-RX-API-DMAC10.html)
AU (1) AU2015306198B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017002926A2 (cg-RX-API-DMAC10.html)
CY (1) CY1124625T1 (cg-RX-API-DMAC10.html)
DK (1) DK3508196T3 (cg-RX-API-DMAC10.html)
ES (1) ES2884849T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20211271T1 (cg-RX-API-DMAC10.html)
HU (1) HUE055711T2 (cg-RX-API-DMAC10.html)
IL (2) IL292079B2 (cg-RX-API-DMAC10.html)
MX (1) MX371417B (cg-RX-API-DMAC10.html)
PL (2) PL3508196T3 (cg-RX-API-DMAC10.html)
PT (1) PT3508196T (cg-RX-API-DMAC10.html)
RS (2) RS58746B2 (cg-RX-API-DMAC10.html)
RU (1) RU2705376C2 (cg-RX-API-DMAC10.html)
SI (2) SI3508196T1 (cg-RX-API-DMAC10.html)
SM (2) SMT202100481T1 (cg-RX-API-DMAC10.html)
WO (1) WO2016026822A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
TR201905694T4 (tr) * 2014-08-18 2019-05-21 Alkermes Pharma Ireland Ltd Aripiprazol ön ilaç bileşimleri.
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
CA3014788A1 (en) 2016-02-17 2017-08-24 Alkermes Pharma Ireland Limited Compositions of multiple aripiprazole prodrugs
CN110025572A (zh) * 2018-01-11 2019-07-19 四川科伦药物研究院有限公司 月桂酰阿立哌唑混悬剂及其制备方法
AU2019230014B2 (en) * 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
WO2022260064A1 (ja) 2021-06-08 2022-12-15 中外製薬株式会社 ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
ES2306452T3 (es) 1995-10-17 2008-11-01 Jagotec Ag Aporte de farmacos insolubles.
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル,リミティド 即時放出および徐放特性を組み合わせて有する組成物
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
DE10350717A1 (de) * 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
WO2007035348A2 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US20120238553A1 (en) 2009-01-27 2012-09-20 Neurosearch A/S Novel benzodioxolyl-oxadiazolyl-diazabicyclononane derivatives and their medical use
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
CA3035442C (en) * 2009-06-25 2022-07-19 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
ES2972387T3 (es) * 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
CA2867121C (en) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
SMT202100212T1 (it) 2014-08-25 2021-07-12 Alkermes Pharma Ireland Ltd Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia
CN105012236A (zh) 2015-08-10 2015-11-04 深圳市泛谷药业有限公司 一种长效非水载体注射液及其制备方法

Also Published As

Publication number Publication date
CA2957762A1 (en) 2016-02-25
RS58746B1 (sr) 2019-06-28
MX2017002029A (es) 2017-08-14
ES2884849T3 (es) 2021-12-13
RS62232B1 (sr) 2021-09-30
RU2705376C2 (ru) 2019-11-07
EP3182958B1 (en) 2019-02-27
CN112494492A (zh) 2021-03-16
AU2015306198B2 (en) 2021-02-25
RU2017108204A (ru) 2018-09-21
HRP20211271T1 (hr) 2022-01-07
PL3508196T3 (pl) 2021-12-20
CN112494492B (zh) 2023-08-25
DK3508196T3 (da) 2021-08-16
IL292079B2 (en) 2024-07-01
NZ767204A (en) 2024-02-23
CY1124625T1 (el) 2022-07-22
EP3182958A1 (en) 2017-06-28
CN106794251B (zh) 2020-12-29
JP2017524021A (ja) 2017-08-24
PL3182958T5 (pl) 2022-09-12
RS58746B2 (sr) 2022-07-29
JP6571166B2 (ja) 2019-09-04
EP3508196A1 (en) 2019-07-10
SMT202100481T1 (it) 2021-09-14
SI3182958T1 (sl) 2019-05-31
CN106794251A (zh) 2017-05-31
IL292079B1 (en) 2024-03-01
EP3182958B2 (en) 2022-05-18
SI3182958T2 (sl) 2022-07-29
HUE055711T2 (hu) 2021-12-28
MX371417B (es) 2020-01-29
BR112017002926A2 (pt) 2017-12-12
PL3182958T3 (pl) 2019-07-31
US12642798B2 (en) 2026-06-02
AU2015306198A1 (en) 2017-03-02
NZ728914A (en) 2023-11-24
EP3508196B1 (en) 2021-07-14
RU2017108204A3 (cg-RX-API-DMAC10.html) 2019-04-04
WO2016026822A1 (en) 2016-02-25
SMT201900236T1 (it) 2019-07-11
IL292079A (en) 2022-06-01
IL250607A0 (en) 2017-04-30
SI3508196T1 (sl) 2021-12-31
CN112641785A (zh) 2021-04-13
IL250607B (en) 2022-05-01
US20220079939A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
GB201419257D0 (en) Pharmaceutical compositions
GB201618482D0 (en) Pharmaceutical compositions
GB201608422D0 (en) Antimicrobial compositions
IL287830A (en) Prodrug compounds of monomethyl fumarate
IL249553A0 (en) Pharmaceutical preparations
IL248223B (en) Compositions of vaccine
HUE055711T2 (hu) Aripiprazol elõvegyület készítmények
HUE050027T2 (hu) Antioxidáns készítmények
GB201408167D0 (en) Compositions
IL251479A0 (en) components
IL250817A0 (en) pharmaceutical preparations
GB201521215D0 (en) Prodrug
GB201420306D0 (en) Compositions
HUE043169T2 (hu) Aripiprazol prodrug készítmények
GB201419849D0 (en) Compositions
GB201411253D0 (en) Prodrug
GB201406863D0 (en) Compositions comprising variegin
GB201415634D0 (en) Novel compositions
SG2014014872A (en) Pharmaceutical compositions
GB201408432D0 (en) Pharmaceutical compositions